P25 Pharmaceutical patent linkage system药品专利链接制度

更新于 2026年11月19日 版权声明
P25 Pharmaceutical patent linkage system药品专利链接制度

【例句】On October 17,2020,the 22nd session of the 13th National People’s Congress(NPC)Standing Committee passed the 4th Amendment to the Patent Law,which unsurprisingly introduces a pharmaceutical patent linkage system.The amendment will take effect on June 1,2021.Article 76 allows the patentee of innovator drugs,the interested party thereof or the generic drug manufacturer seeking marketing approval to bring,during,rather than post,the regulatory approval process,a suit to the court.It can also request an administrative adjudication from the patent administration authority to ascertain whether the technical solutions of the generic drug to be marketed fall within the scope of protection of the related patent.The state drug administration authority may stay review of the application for market approval of a generic drug based on an effective court ruling.(Jie Zhao,China embraces a pharmaceutical patent linkage system https://www.managingip.com/article/2a5cxt3jlqj6c6jkf9xc0/china-embraces-a-pharmaceutical-patent-linkage-system)

【译文】2020年10月17日,第十三届全国人民代表大会(NPC)常务委员会第二十二次会议通过了《中华人民共和国专利法》(第四次修正案),引入了药品专利链接制度。该修正案将于2021年6月1日生效。第七十六条规定药品上市审评审批过程中,药品上市许可申请人与有关专利权人或者利害关系人,因申请注册的药品相关的专利权产生纠纷的,相关当事人可以向人民法院起诉,请求就申请注册的药品相关技术方案是否落入他人药品专利权保护范围作出判决。国务院药品监督管理部门在规定的期限内,可以根据人民法院生效裁判作出是否暂停批准相关药品上市的决定。(https://www.daowen.com)

【练习】Jointly drafted by the NMPA and the CNIPA,the exposure draft for the Implementation Measures for Early Resolution Mechanism of Pharmaceutical Patent Disputes(for Trial Implementation),which was released on September 11,2020 to solicit public opinion,is probably the nearest thing to a detailed measure regarding a pharmaceutical patent linkage system。

✍AI写作